25K0
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more
25K0 (25K0) - Net Assets
Latest net assets as of September 2025: €-269.26 Million EUR
Based on the latest financial reports, 25K0 (25K0) has net assets worth €-269.26 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€96.23 Million) and total liabilities (€365.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-269.26 Million |
| % of Total Assets | -279.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
25K0 - Net Assets Trend (2021–2024)
This chart illustrates how 25K0's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 25K0 (2021–2024)
The table below shows the annual net assets of 25K0 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-186.02 Million | -36.57% |
| 2023-12-31 | €-136.21 Million | -717.76% |
| 2022-12-31 | €-16.66 Million | +79.09% |
| 2021-12-31 | €-79.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 25K0's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38481200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.38 Billion | % |
| Total Equity | €-186.02 Million | 100.00% |
25K0 Competitors by Market Cap
The table below lists competitors of 25K0 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GTC
F:G91
|
$102.39 Million |
|
Kofola CeskoSlovensko as
PR:KOFOL
|
$102.40 Million |
|
EKF DIAGNOST.HLDGS.LS-01
F:LYF
|
$102.41 Million |
|
Major-Power Technology Co., Ltd.
TWO:6720
|
$102.44 Million |
|
Goltas Goller Bolgesi Cimento Sanayi ve Ticaret AS
IS:GOLTS
|
$102.39 Million |
|
NMPRY
PINK:NMPRY
|
$102.35 Million |
|
Tolu Minerals Ltd
AU:TOK
|
$102.35 Million |
|
COSMO FIRST LIMITED
NSE:COSMOFIRST
|
$102.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 25K0's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -136,206,000 to -186,017,000, a change of -49,811,000.
- Net loss of 76,422,000 reduced equity.
- Other factors increased equity by 26,611,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-76.42 Million | -41.08% |
| Other Changes | €26.61 Million | +14.31% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares 25K0's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-15.78 | €6.85 | x |
| 2022-12-31 | €-2.21 | €6.85 | x |
| 2023-12-31 | €-17.78 | €6.85 | x |
| 2024-12-31 | €-22.11 | €6.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 25K0 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -52.62%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -59.14% | 0.69x | 0.00x | €-116.12 Million |
| 2022 | 0.00% | -105.23% | 0.44x | 0.00x | €-163.63 Million |
| 2023 | 0.00% | -97.99% | 0.61x | 0.00x | €-129.48 Million |
| 2024 | 0.00% | -52.62% | 0.88x | 0.00x | €-57.82 Million |
Industry Comparison
This section compares 25K0's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,436,388,532
- Average return on equity (ROE) among peers: -27.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 25K0 (25K0) | €-269.26 Million | 0.00% | N/A | $102.39 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |